Literature DB >> 18726243

Cardiovascular protection for all individuals at high risk: evidence-based best practice.

George Bakris1, Michael Böhm, Gilles Dagenais, Hans-Christoph Diener, Toshiro Fujita, Philip Gorelick, Sverre Erik Kjeldsen, Markku Laakso, Giuseppe Mancia, Bertram Pitt, Arya Sharma, Peter Sleight, Koon Teo, Thomas Unger, Michael Weber, Bryan Williams, Faiez Zannad.   

Abstract

Patients with cardiovascular risk factors are largely undertreated, for many reasons. Vulnerable individuals may not be aware of the risks they are facing or an individual's risk of cardiovascular disease may be underestimated, particularly among those at high risk. Furthermore, in individuals identified as being at high total cardiovascular risk, the full spectrum of therapeutic options may not be implemented or patients may not adhere to the treatment prescribed. We address these critical issues by summarizing the existing guidelines: our ultimate goal is to encourage the optimal management of individuals at high total cardiovascular risk according to evidence-based medicine, with the expectation that this will improve outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18726243     DOI: 10.1007/s00392-008-0713-2

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  76 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  High-dose atorvastatin after stroke or transient ischemic attack.

Authors:  Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

3.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

4.  A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.

Authors:  Deepak L Bhatt; Keith A Fox; Werner Hacke; Peter B Berger; Henry R Black; William E Boden; Patrice Cacoub; Eric A Cohen; Mark A Creager; J Donald Easton; Marcus D Flather; Steven M Haffner; Christian W Hamm; Graeme J Hankey; S Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A Pearson; P Gabriel Steg; Steven R Steinhubl; Michael A Weber; Joan Booth; Eric J Topol
Journal:  Am Heart J       Date:  2005-09       Impact factor: 4.749

5.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

6.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

7.  Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes.

Authors:  Mihaela Tanasescu; Michael F Leitzmann; Eric B Rimm; Frank B Hu
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

8.  Does patient education in chronic disease have therapeutic value?

Authors:  S A Mazzuca
Journal:  J Chronic Dis       Date:  1982

Review 9.  Rationale for double renin-angiotensin-aldosterone system blockade.

Authors:  Thomas Unger; Martina Stoppelhaar
Journal:  Am J Cardiol       Date:  2007-05-25       Impact factor: 2.778

10.  Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.

Authors:  Sonia Anand; Salim Yusuf; Changchun Xie; Janice Pogue; John Eikelboom; Andrzej Budaj; Bruce Sussex; Lisheng Liu; Randy Guzman; Claudio Cina; Richard Crowell; Matyas Keltai; Gilbert Gosselin
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

View more
  5 in total

1.  Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry).

Authors:  Anselm K Gitt; Claus Jünger; Christina Jannowitz; Barbara Karmann; Jochen Senges; Kurt Bestehorn
Journal:  Clin Res Cardiol       Date:  2010-10-21       Impact factor: 5.460

Review 2.  [Erectile dysfunction: indicator of end-organ damage in cardiovascular patients].

Authors:  Magnus Baumhäkel; Nils Schlimmer; Mario T Kratz; Michael Böhm
Journal:  Med Klin (Munich)       Date:  2009-04-15

Review 3.  Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials.

Authors:  Magnus Baumhäkel; Michael Böhm
Journal:  Vasc Health Risk Manag       Date:  2011-06-23

4.  Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension.

Authors:  Julian Segura; Luis M Ruilope
Journal:  Integr Blood Press Control       Date:  2011-05-19

Review 5.  Hotline update of clinical trials and registries presented at the German Cardiac Society Meeting 2009.

Authors:  L S Maier; S H Schirmer; K Walenta; C Jacobshagen; M Böhm
Journal:  Clin Res Cardiol       Date:  2009-05-26       Impact factor: 5.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.